NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, Price Target & More

$7.00 -0.02 (-0.28 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$7.00

Today's Range$6.95 - $7.10

52-Week Range$4.60 - $8.63

Volume516,810 shs

Average Volume1.22 million shs

Market Capitalization$510.09 million

P/E Ratio-7.78

Dividend YieldN/A

Beta2.46

About Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:PGNX

CUSIP74318710

Webwww.progenics.com

Phone646-975-2500

Debt

Debt-to-Equity Ratio0.74%

Current Ratio6.31%

Quick Ratio6.31%

Price-To-Earnings

Trailing P/E Ratio-7.78

Forward P/E Ratio-8.75

P/E GrowthN/A

Sales & Book Value

Annual Sales$11.70 million

Price / Sales43.47

Cash FlowN/A

Price / CashN/A

Book Value$0.90 per share

Price / Book7.78

Profitability

EPS (Most Recent Fiscal Year)($0.90)

Net Income$-51,010,000.00

Net Margins-436.08%

Return on Equity-87.30%

Return on Assets-38.46%

Miscellaneous

Employees64

Outstanding Shares72,660,000

How to Become a New Pot Stock Millionaire

Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) posted its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.21) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.21). The biotechnology company had revenue of $3.90 million for the quarter, compared to analysts' expectations of $3.18 million. Progenics Pharmaceuticals had a negative return on equity of 87.30% and a negative net margin of 436.08%. The business's quarterly revenue was down 15.2% on a year-over-year basis. During the same period last year, the firm earned ($0.10) earnings per share. View Progenics Pharmaceuticals' Earnings History.

When is Progenics Pharmaceuticals' next earnings date?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Progenics Pharmaceuticals.

What price target have analysts set for PGNX?

4 analysts have issued 12-month target prices for Progenics Pharmaceuticals' stock. Their forecasts range from $12.00 to $15.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $13.75 in the next year. View Analyst Ratings for Progenics Pharmaceuticals.

What are Wall Street analysts saying about Progenics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:

1. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (4/7/2018)
2. Cantor Fitzgerald analysts commented, "PGNX has completed the rolling NDA for AZEDRA for pheochromocytoma and paraganglioma." (11/2/2017)

Who are some of Progenics Pharmaceuticals' key competitors?

Some companies that are related to Progenics Pharmaceuticals include CytomX Therapeutics (CTMX), Uniqure (QURE), MacroGenics (MGNX), Biohaven Pharmaceutical (BHVN), Alder BioPharmaceuticals (ALDR), Assembly Biosciences (ASMB), Access Pharmaceuticals (ABEO), Flexion Therapeutics (FLXN), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), Inflarx (IFRX), ARMO BioSciences (ARMO), Collegium Pharmaceutical (COLL), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Deciphera Pharmaceuticals (DCPH) and Urogen Pharma (URGN).

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the folowing people:

Peter J. Crowley, Independent Chairman of the Board (Age 59)
Mark R. Baker J.D., , Chief Executive Officer, Director (Age 62)
Patrick Fabbio, Chief Financial Officer, Senior Vice President (Age 49)
Vivien Wong Ph.D., Executive Vice President - Development (Age 60)
Jeffrey D. Summer, Senior Vice President - Strategy and Performance (Age 57)
Bryce Tenbarge, Vice President - Commercial (Age 44)
Bradley L. Campbell, Independent Director (Age 41)
Karen Jean Ferrante M.D., Independent Director (Age 59)
Michael D. Kishbauch, Independent Director (Age 68)
David A. Scheinberg MD., Ph.D., Independent Director (Age 61)

Has Progenics Pharmaceuticals been receiving favorable news coverage?

News stories about PGNX stock have been trending positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of 0.29 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Progenics Pharmaceuticals?

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $7.00.

How big of a company is Progenics Pharmaceuticals?

Progenics Pharmaceuticals has a market capitalization of $510.09 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]

MarketBeat Community Rating for Progenics Pharmaceuticals (PGNX)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		230 (Vote Outperform)
Underperform Votes:		176 (Vote Underperform)
Total Votes:		406

MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Progenics Pharmaceuticals (NASDAQ:PGNX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for Progenics Pharmaceuticals in the last 12 months. Their average twelve-month price target is $13.75, suggesting that the stock has a possible upside of 96.43%. The high price target for PGNX is $15.00 and the low price target for PGNX is $12.00. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.25	3.25	3.25	3.20
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$13.75	$13.75	$13.75	$13.20
Price Target Upside:	96.43% upside	64.47% upside	123.58% upside	86.44% upside

Progenics Pharmaceuticals (NASDAQ:PGNX) Consensus Price Target History

Price Target History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ:PGNX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/22/2018	Cantor Fitzgerald	Set Price Target	Buy	$15.00	High
9/1/2017	Needham & Company LLC	Reiterated Rating	Strong-Buy	$14.00	Medium
8/22/2017	Aegis	Reiterated Rating	Buy	$14.00	Low
6/8/2017	Jefferies Group	Reiterated Rating	Buy	$12.00	High
11/30/2016	BTIG Research	Boost Price Target	Buy	$9.00 -> $11.00	N/A
10/4/2016	Brean Capital	Initiated Coverage	Buy	$11.00	N/A

(Data available from 4/21/2016 forward)

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings History and Estimates Chart

Earnings by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.83)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.23)	($0.23)	($0.23)
Q2 2018	1	($0.24)	($0.24)	($0.24)
Q3 2018	1	($0.24)	($0.24)	($0.24)
Q4 2018	1	($0.12)	($0.12)	($0.12)

Progenics Pharmaceuticals (NASDAQ PGNX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		($0.19)					N/A
3/8/2018	Q4 2017	($0.21)	($0.21)	$3.18 million	$3.90 million	View	N/A
11/2/2017	Q3 2017	($0.24)	($0.22)	$3.58 million	$2.70 million	View	N/A
8/9/2017	Q2 2017	($0.20)	($0.24)	$3.34 million	$2.77 million	View	Listen
5/4/2017	Q1 2017	($0.16)	($0.23)	$4.50 million	$2.40 million	View	Listen
3/9/2017	Q4 2016	($0.20)	($0.10)	$4.43 million	$4.65 million	View	Listen
11/7/2016	Q316	$0.55	$0.52	$52.90 million	$53.90 million	View	Listen
8/4/2016	Q216	($0.13)	($0.08)	$6.33 million	$8.50 million	View	N/A
5/5/2016	Q116	($0.13)	($0.18)	$3.27 million	$2.50 million	View	Listen
3/11/2016	Q415	($0.14)	($0.10)	$2.25 million	$5.10 million	View	Listen
11/9/2015	Q315	($0.13)	($0.14)	$2.35 million	$1.40 million	View	Listen
8/6/2015	Q215	($0.15)	($0.17)	$1.63 million	$1.90 million	View	Listen
5/6/2015	Q115	($0.16)	($0.15)	$1.30 million	$0.25 million	View	N/A
3/16/2015	Q414	($0.13)	($0.18)	$2.87 million	($0.57) million	View	N/A
11/7/2014	Q314	($0.16)	$0.51	$2.50 million	$41.66 million	View	N/A
8/8/2014	Q214	($0.14)	($0.17)	$2.83 million	$1.50 million	View	Listen
5/9/2014	Q114	($0.15)	($0.15)	$2.88 million	$1.80 million	View	N/A
3/13/2014	Q4	($0.19)	($0.14)	$1.48 million	$3.00 million	View	Listen
3/3/2014	Q4 2013	($0.19)	($0.14)	$1.74 million	$2.97 million	View	N/A
11/11/2013	Q313	($0.22)	($0.17)	$2.00 million	$0.90 million	View	N/A
8/9/2013	Q2 2013	($0.24)	($0.24)	$1.86 million	$1.80 million	View	N/A
5/10/2013	Q1 2013	($0.19)	($0.22)	$1.71 million	$2.23 million	View	N/A
3/15/2013	Q4 2012	($0.31)	($0.01)	$1.16 million	$8.87 million	View	N/A
11/8/2012	Q312	($0.30)	($0.33)	$2.52 million	$1.10 million	View	N/A
8/9/2012		($0.32)	($0.32)			View	N/A
5/8/2012		($0.33)	($0.39)			View	N/A
3/15/2012	Q4 2011	($0.25)	($0.32)			View	N/A
11/9/2011		($0.33)	($0.34)			View	N/A
8/9/2011		($0.25)	$1.64			View	N/A
5/10/2011		($0.51)	($0.69)			View	N/A
3/15/2011		($0.57)	($0.57)			View	N/A
11/8/2010	Q3 2010	($0.56)	($0.52)			View	N/A
8/9/2010	Q2 2010	($0.54)	($0.47)			View	N/A
5/10/2010	Q1 2010	($0.41)	($0.58)			View	N/A
3/15/2010	Q4 2009	($0.14)	($0.02)			View	N/A
11/9/2009	Q3 2009	($0.44)	($0.41)			View	N/A
8/6/2009	Q2 2009	($0.50)	($0.50)			View	N/A
5/11/2009	Q1 2009	($0.27)	($0.06)			View	N/A
3/13/2009	Q4 2008	($0.30)	($0.49)			View	N/A
11/10/2008	Q3 2008	($0.28)	($0.41)			View	N/A
8/8/2008	Q2 2008	$0.01	($0.08)			View	N/A
5/9/2008	Q1 2008	($0.41)	($0.52)			View	N/A
3/17/2008	Q4 2007	($0.46)	($0.53)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Progenics Pharmaceuticals (NASDAQ:PGNX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.63%
Institutional Ownership Percentage: 83.75%

Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/15/2017	Healthcare Master Fun Broadfin	Major Shareholder	Sell	602,600	$9.66	$5,821,116.00
2/9/2017	Healthcare Master Fun Broadfin	Major Shareholder	Sell	351,300	$9.71	$3,411,123.00
6/11/2015	Robert J Israel	EVP	Sell	2,000	$6.83	$13,660.00
3/13/2015	Robert J Israel	EVP	Sell	3,000	$7.00	$21,000.00
3/11/2015	Robert J Israel	EVP	Sell	2,000	$6.83	$13,660.00
3/3/2015	Robert J Israel	EVP	Sell	5,000	$6.49	$32,450.00
1/12/2015	Robert J Israel	EVP	Sell	2,000	$7.06	$14,120.00
12/11/2014	Robert J Israel	EVP	Sell	3,000	$7.07	$21,210.00
11/21/2014	Robert J Israel	EVP	Sell	9,000	$7.00	$63,000.00
11/13/2014	Robert J Israel	EVP	Sell	10,000	$6.83	$68,300.00
11/11/2014	Robert J Israel	EVP	Sell	5,000	$6.53	$32,650.00
7/21/2014	Healthcare Master Fun Broadfin	Major Shareholder	Buy	1,625,436	$4.60	$7,477,005.60
7/18/2014	Healthcare Master Fun Broadfin	Major Shareholder	Buy	388,200	$4.73	$1,836,186.00
7/17/2014	Healthcare Master Fun Broadfin	Major Shareholder	Buy	436,884	$4.48	$1,957,240.32
7/16/2014	Healthcare Master Fun Broadfin	Major Shareholder	Buy	411,693	$4.48	$1,844,384.64
7/18/2013	Robert J Israel	VP	Sell	5,000	$6.33	$31,650.00
2/27/2013	Mark Robert Baker	CEO	Buy	1,262	$2.72	$3,432.64
1/22/2013	Mark Robert Baker	CEO	Buy	1,215	$2.82	$3,426.30
12/26/2012	Mark Robert Baker	CEO	Buy	1,142	$3.01	$3,437.42
11/28/2012	Mark Robert Baker	CEO	Buy	1,607	$2.13	$3,422.91
11/19/2012	Mark Robert Baker	CEO	Buy	11,800	$1.96	$23,128.00
11/16/2012	Mark Robert Baker	CEO	Buy	49,793	$1.82	$90,623.26
11/15/2012	Mark Robert Baker	CEO	Buy	48,833	$1.69	$82,527.77
10/24/2012	Mark Robert Baker	CEO	Buy	1,162	$2.96	$3,439.52
9/26/2012	Mark Robert Baker	CEO	Buy	1,036	$3.32	$3,439.52

(Data available from 1/1/2013 forward)

Progenics Pharmaceuticals (NASDAQ PGNX) News Headlines

Source:

Date	Headline
	Progenics Pharmaceuticals (PGNX) Downgraded by BidaskClub www.americanbankingnews.com - April 21 at 7:24 AM
	Progenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 19 at 12:49 PM
	Progenics Pharmaceuticals, Inc. (PGNX) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 19 at 5:56 AM
	Cantor Fitzgerald Begins Coverage on Progenics Pharmaceuticals (PGNX) www.americanbankingnews.com - April 18 at 8:34 PM
	Progenics Pharmaceuticals (PGNX) PT Set at $15.00 by Cantor Fitzgerald www.americanbankingnews.com - April 11 at 7:19 PM
	Progenics Talks Commercialization, Pipeline, And Milestones seekingalpha.com - April 10 at 9:29 AM
	Progenics Pharmaceuticals' (PGNX) Buy Rating Reaffirmed at Aegis www.americanbankingnews.com - April 9 at 10:55 PM
	Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research to "Sell" www.americanbankingnews.com - April 7 at 7:02 AM
	Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 6 at 6:29 PM
	Equities Analysts Set Expectations for Progenics Pharmaceuticals, Inc.'s FY2018 Earnings (PGNX) www.americanbankingnews.com - April 6 at 7:24 AM
	Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at Zacks Investment Research www.americanbankingnews.com - April 1 at 11:52 AM
	Progenics Pharmaceuticals (PGNX) Given a $15.00 Price Target at Cantor Fitzgerald www.americanbankingnews.com - March 31 at 10:54 AM
	Progenics Pharmaceuticals (PGNX) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - March 30 at 6:15 PM
	Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at ValuEngine www.americanbankingnews.com - March 28 at 12:24 PM
	Progenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - March 25 at 5:32 AM
	3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News seekingalpha.com - March 24 at 5:12 PM
	Progenics Pharmaceuticals (PGNX) Rating Increased to Buy at BidaskClub www.americanbankingnews.com - March 24 at 3:52 PM
	Is the FDA Expecting More Problems for Progenics? - 24/7 Wall St. 247wallst.com - March 24 at 8:19 AM
	Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Expected To Breakeven finance.yahoo.com - March 23 at 9:03 AM
	Progenics Pharma (PGNX) Announces Three-Month Extension of PDUFA Date for AZEDRA - StreetInsider.com www.streetinsider.com - March 22 at 4:53 PM
	Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131) - GlobeNewswire (press release) globenewswire.com - March 22 at 4:53 PM
	Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131) finance.yahoo.com - March 22 at 4:53 PM
	5 Big Biotech Stocks to Buy Under $10 - Investorplace.com investorplace.com - March 20 at 4:49 PM
	Progenics Pharmaceuticals Announces Presentation of AZEDRA ... - Nasdaq www.nasdaq.com - March 20 at 4:49 PM
	Progenics Pharmaceuticals, Upcoming PDUFA Date, Analysts Target Price, Pipeline Review finance.yahoo.com - March 20 at 9:14 AM
	Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference finance.yahoo.com - March 20 at 9:14 AM
	Our Post-Earnings Take On Progenics Pharmaceuticals - Seeking Alpha seekingalpha.com - March 13 at 4:59 PM
	Progenics Pharmaceuticals, Inc. (PGNX) to Post Q1 2018 Earnings of ($0.23) Per Share, Jefferies Group Forecasts www.americanbankingnews.com - March 12 at 1:52 AM
	Progenics Pharmaceuticals (PGNX) Upgraded at BidaskClub www.americanbankingnews.com - March 10 at 11:34 PM
	Progenics Pharmaceuticals (PGNX) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS www.americanbankingnews.com - March 8 at 2:45 PM
	Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update finance.yahoo.com - March 8 at 10:31 AM
	Progenics Pharmaceuticals reports Q4 results seekingalpha.com - March 8 at 8:15 AM
	Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Trading At A 41.88% Discount To Its Intrinsic Value finance.yahoo.com - March 5 at 4:49 PM
	Investors Purchase Large Volume of Put Options on Progenics Pharmaceuticals (PGNX) www.americanbankingnews.com - March 2 at 7:30 AM
	Traders Buy High Volume of Call Options on Progenics Pharmaceuticals (PGNX) www.americanbankingnews.com - March 2 at 7:28 AM
	Fuller & Thaler Asset Management Inc. Sells 106,400 Shares of Progenics Pharmaceuticals, Inc. (PGNX) www.americanbankingnews.com - March 1 at 10:50 AM
	Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2017 Financial Results Call for March 8 finance.yahoo.com - March 1 at 9:25 AM
	Carillon Tower Advisers Inc. Invests $21.79 Million in Progenics Pharmaceuticals, Inc. (PGNX) www.americanbankingnews.com - March 1 at 5:38 AM
	Progenics Pharmaceuticals, Inc. (PGNX) Shares Sold by Royce & Associates LP www.americanbankingnews.com - February 28 at 9:42 AM
	Progenics Pharmaceuticals (PGNX) Set to Announce Quarterly Earnings on Wednesday www.americanbankingnews.com - February 28 at 1:40 AM
	KBC Group NV Has $1.30 Million Stake in Progenics Pharmaceuticals, Inc. (PGNX) www.americanbankingnews.com - February 25 at 6:40 AM
	Progenics Pharmaceuticals (PGNX) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow seekingalpha.com - February 23 at 4:42 PM
	Progenics Pharmaceuticals (PGNX) Lifted to Hold at BidaskClub www.americanbankingnews.com - February 18 at 1:00 PM
	Progenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference finance.yahoo.com - February 15 at 4:46 PM
	Progenics Pharmaceuticals Sees Unusually High Options Volume (PGNX) www.americanbankingnews.com - February 14 at 5:50 PM
	Progenics Pharmaceuticals (PGNX) Presents At BIO CEO & Investor Conference - Slideshow seekingalpha.com - February 14 at 3:27 PM
	Progenics Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference finance.yahoo.com - February 5 at 3:24 PM
	Progenics Pharmaceuticals, Inc. (PGNX) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - February 3 at 5:28 AM
	Progenics Pharma (PGNX) Announces Presentation of AZEDRA Biochemical Tumor Marker Data at ENDO - StreetInsider.com www.streetinsider.com - February 2 at 6:28 AM
	Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting feeds.benzinga.com - February 1 at 5:13 PM

Progenics Pharmaceuticals (NASDAQ:PGNX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Progenics Pharmaceuticals (NASDAQ:PGNX) Income Statement, Balance Sheet and Cash Flow Statement

Progenics Pharmaceuticals (NASDAQ PGNX) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff